| Assessment Status | Awaiting HTA submission from Applicant |
| HTA ID | 22067 |
| Drug | Bulevirtide |
| Brand | Hepcludex® |
| Indication | Chronic hepatitis delta (CHD) infection in plasma (or serum) HDV RNA-positive adult patients with compensated liver disease. |
| Assessment Process | |
| Rapid review commissioned | 06/10/2022 |
| Rapid review completed | 10/11/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of bulevirtide compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 30/11/2022 |
| Pre-submission consultation with Applicant | 10/01/2023 |
